Biogen Inc BIIB:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
284.20 -3.43   -1.19%756,4861.8M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Chart as of 01:20 PM ET 2/23/2017

Latest News Headlines for Biogen Inc

Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 15, 2017-- Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference. The webcast will be live on Wednesday, February 22, 2017 at 3:05 p.m. EST. To access the live webcast, please visit Biogen's Investors section at An archived version of the webcast will be available following the presentation.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Allergan plc
Mylan NV
Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Allergan plc
Mylan NV
Biogen Inc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Allergan plc
Mylan NV
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open287.75
Previous Close287.63
Day High288.11
Day Low283.36
52 Week High8/2/2016 | 307.325
52 Week Low6/27/2016 | 205.4247
% Off 52 Week High(7.52)%
% Off 52 Week Low38.35%
Beta (5 Yr)0.79
Volatility Avg2/22/2017 | 32.39
10-Day Avg. Volume1,814,738
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)12/31/2016 | 16.91
P/E Ratio12/31/2016 | 17.0
Market CapLarge Cap | 61.4B
Shares Outstanding215.95M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short1.90M
Short Ratio1.0
Short % of Float0.88%
As of 1/31/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.